PitchBook clients can access the complete Excel data pack via the Research Center on the PitchBook Platform.
Biomanufacturing, AI, and multiomics platforms drive pharma biotools investment momentum
VC deal activity in pharma biotools investment remained strong in Q2 2025, with 102 deals totaling nearly $1 billion in funding. Consistent activity has put 2025 on pace for record annual deal count, even as total capital invested remains far below historical averages. Investor interest in emerging technologies such as AI drug discovery, multiomics, and lab automation is driving strong seed and early-stage dealmaking. Notable deals of the quarter included Vivodyne and Parallel Bio, which both raised sizable rounds for their human organ models. With a new investor focus on domestic manufacturing, biomanufacturing and synthetic biology also saw an uptick in investment.
Exit activity in the vertical is picking up as well, with the 18 exits in 2025 already surpassing last year’s total. However, large transactions remain scarce, as strategic M&A has accounted for nearly all exits this year. Major exits from Q2 included Bio-Rad’s $225 million acquisition of Stilla Technologies and the $250 million sale of Evergreen Theragnostics to Lantheus Medical Imaging.
Table of contents
| Pharma biotools landscape | 3 |
| Pharma biotools VC ecosystem market map | 4 |
| VC activity | 5 |
| Pharma biotools VC deal summary | 22 |